PT  - JOURNAL ARTICLE
AU  - Saha, Dipankar
AU  - Chowdhury, Prosanto Kumar
AU  - Panja, Amrita
AU  - Pal, Debashis
AU  - Chakraborty, Sharmistha
AU  - Nayek, Kaustav
AU  - Chakraborty, Gispati
AU  - Sharma, Prashant
AU  - Das, Reena
AU  - Basu, Surupa
AU  - Chatterjee, Raghunath
AU  - Basu, Anupam
TI  - Alpha globin gene deletions in amelioration of clinical severity in beta haemoglobinopathy subjects with the β<sup>0</sup>/β<sup>+</sup> genotype
AID  - 10.1101/2020.05.29.20117135
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.29.20117135
4099  - http://medrxiv.org/content/early/2020/05/30/2020.05.29.20117135.short
4100  - http://medrxiv.org/content/early/2020/05/30/2020.05.29.20117135.full
AB  - Thalassemia is the commonest inherited hemoglobinopathy worldwide. Variation of clinical symptoms entail differences in disease-onset and transfusion requirements. Our objective was to investigate the role of alpha gene deletions in modulating the clinical heterogeneity of thalassemia syndromes. A total of 214 individuals with diagnosed beta-thalassemia major/intermedia were included in the study. Beta globin mutations were determined and categorized as β+ and β0. Eight common alpha globin gene deletions were detected by multiplex GAP-PCR. Out of the 17 individuals with β+/β+, 16 did not harbour alpha deletions (αα/αα), and most of them were non-severe. On the other hand, out of 46 individuals with β0/β0, 30 did not reveal alpha deletions, whereas 16 possessed one or more alpha deletion(s). Accordingly, most of them presented as clinically severe. Out of the 151 β0/β+ individuals, 119 were negative for alpha deletion, whereas 32 possessed alpha deletions. It was observed that, only in this last category, alpha deletions made a significant contribution (P< 0.0001) in modulation of clinical non severity in this genotype. In conclusion, alpha globin gene deletions play a role to help in ameliorating the phenotype in the β+/β0 genotype. However, they may have only minor/no role in patients with β+/β+ or β0/β0 genotype.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDepartment of Science and Technology and Biotechnology, Govt of West Bengal, for supporting this work [Sanc.No- 687(Sanc.)/ST/P/S&T/1G-20/2014]. The authors are also thankful to Department of Biotechnology, Govt of India for supporting this work [Sanc. No-BT/PR26461/MED/12/821/2018Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Clinical Ethics Committee, The University of BurdwanAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIf requested primary data will be provided